Spotlight

The ACCC promotes competition and fair trade in markets to benefit consumers, businesses, and the community. ​In May this year, Apotex Australia announced a merger of their Australian

The company is restructuring its R&D organization to accelerate the expansion and diversification of its pipeline across severe chronic diseases, in addition to supporting increased investment in transformational

ViraTherapeutics is engaged in the development of virus-based immunotherapeutics for the treatment of cancer. The current deal is based on an option and share purchase agreement signed by

To encourage Regeneron’s expansion in New York State, Empire State Development offered the company up to $140 million in performance-based incentives, including $70 million in Excelsior Jobs Program

GSK recently revealed its target of generating annual cost savings of £400m by 2021 by implementing the restructuring program across the group. The restructuring program was taken up

Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for

Merkel cell carcinoma is a rare form of skin cancer caused by a Merkel cell associated polyomavirus. The company’s supplemental biologics license application (sBLA), which has been accepted

The FDA in its complete response letter issued to the company conveyed that the new drug application (NDA) for dasotraline could not be approved in its current form.

The study results, as well as the results of Sonoma’s previous HOCl acne studies (total of 127 patients), were presented by the principal investigator, Mark Steven Nestor, M.D.,